en · de · es · fr · pt
peptide-index.peptides6823.com › Wiki › Background And Research Context — Research Overview

Background And Research Context — Research Overview

By Editorial Desk · published 2025-09-21 · last reviewed 2025-10-31 · Wiki

The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-10-31. Anything still debated is marked as such rather than presented as settled.

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

Related pages on this site

Handling And Analytical Properties

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Reference notes

A brown recluse's stance on a flat surface is usually with all legs radially extended. When alarmed it may lower its body, withdraw the forward two legs straight rearward into a defensive position, withdraw the rearmost pair of legs into a position for lunging forward, and stand motionless with pedipalps raised. The pedipalps in mature specimens are dark and quite prominent and are normally held horizontally forward. When threatened it usually flees, seemingly to avoid a conflict, and if detained may further avoid contact with quick horizontal rotating movements or even resort to assuming a lifeless pose (playing dead). The spider does not usually jump unless touched brusquely, and even then its avoidance movement is more of a horizontal lunge rather than a vaulting of itself entirely off the surface. When running, the brown recluse does not leave a silk line behind, which would make it more easily tracked when it is being pursued. Movement at virtually any speed is an evenly paced gait with legs extended. The brown recluse spider displays autotomy as a defense mechanism against physical, predatory attack to a leg as well as to prevent predatory, venom injections from spreading to the rest of the body. "Once a leg is lost, a recluse spider does not regenerate a new one with subsequent molts", unlike the huntsman spider, which does regenerate autotomized legs. With each time that a leg is autotomized, the recluse "changes its gait to compensate for the loss."

AMP + diphosphate + GMP + L-glutamate The 4 substrates of this enzyme are ATP, xanthosine 5'-phosphate, L-glutamine, and H2O, whereas its 4 products are AMP, diphosphate, GMP, and L-glutamate. This enzyme belongs to the family of ligases, specifically those forming carbon-nitrogen bonds carbon-nitrogen ligases with glutamine as amido-N-donor. The systematic name of this enzyme class is xanthosine-5'-phosphate:L-glutamine amido-ligase (AMP-forming). This enzyme participates in purine metabolism and glutamate metabolism. At least one compound, Psicofuranin is known to inhibit this enzyme.

His publications also highlight the importance of patient happiness, as well as the well-being of the treating physician. Strengthening family support, advancing social acceptance, and addressing patient emotions are other elements he considers essential to delivering person-centred care.69 He has also highlighted the value of indigenous methods for lifestyle modification and personal hygiene in improving person-centred care.123,166 Kalra has proposed several frameworks to help clinicians integrate the above principles into routine practice.129,161,162 These frameworks have been widely cited. In collaboration with researchers in Morocco, he published the SURE framework outlining the “glycaemic personality” of patients, enabling more tailored therapeutic choices. In another publication, he described the Motivation–Opportunity–Capability (MOC) model for obesity care, underscoring the importance of understanding patient behaviour and aligning therapeutic approaches with their opportunities and capabilities. Kalra’s contribution to original research includes participation in multicentric international collaborative studies that have advanced understanding of person-centred management. In the three-year, pan-India longitudinal study on diabetes outcomes (the LANDMARC trial), data are being collected on trends in diabetic complications, physician treatment strategies, and correlations between treatment, control, and complications in the Indian setting.

Algaecide or algicide is a biocide used for killing and preventing the growth of algae, often defined in a loose sense that, beyond the biological definition, also includes cyanobacteria ("blue-green algae"). An algaecide may be used for controlled bodies of water (reservoirs, golf ponds, swimming pools), but may also be used on land for locations such as turfgrass.

=== Buc–But === Eduard Buchner (1860–1917), German chemist who sounded the death knell of vitalism by discovering cell-free fermentation, 1907 Nobel Prize in Chemistry Stephen L. Buchwald (born 1955), American organic chemist, co-discoverer of palladium-catalyzed C–N bond formation Buchwald–Hartwig amination Mary Van Rensselaer Buell (1893–1969), American chemist who worked on nucleic acids and nucleotides, the relation of hormones to the metabolism of carbohydrates, and other topics in biochemistry Kathryn Bullock (1945–2021), American chemist who co-developed valve-regulated lead-acid batteries Robert Wilhelm Bunsen (1811–1899), German inventor, chemist, discovered the elements caesium and rubidium with Gustav Kirchhoff and invented the Bunsen burner Jeanne Burbank (1915–2002), American chemist who developed lead-acid and silver-zinc batteries for submarines at the United States Naval Research Laboratory Stephanie Burns (born 1955), American organosilicon chemist and past honorary president of Society of Chemical Industry William Merriam Burton (1865–1954), American chemist, developed the first thermal cracking process for crude oil Adolf Butenandt (1903–1995), German biochemist, 1939 Nobel Prize in Chemistry for "work on sex hormones" Alison Butler (PhD 1982), American bioinorganic chemist and metallobiochemist Aleksandr Butlerov (1828–1886), Russian chemist, one of the creators of the theory of chemical structure, who discovered the formose reaction

Sources: en.wikipedia.org

Reference notes

In humans, adipose tissue is located beneath the skin (subcutaneous fat), around internal organs (visceral fat), in bone marrow (yellow bone marrow), intermuscular (muscular system), and in the breast (breast tissue). Adipose tissue is found in specific locations, which are referred to as adipose depots. In addition to adipocytes, which comprise the highest percentage of cells within adipose tissue, other cell types are present, collectively termed stromal vascular fraction (SVF) of cells. SVF includes preadipocytes, fibroblasts, adipose tissue macrophages, and endothelial cells. Adipose tissue contains many small blood vessels. In the integumentary system, which includes the skin, it accumulates in the deepest level, the subcutaneous layer, providing insulation from heat and cold. Around organs, it provides protective padding. However, its main function is to be a reserve of lipids, which can be oxidised to meet the energy needs of the body and to protect it from excess glucose by storing triglycerides produced by the liver from sugars, although some evidence suggests that most lipid synthesis from carbohydrates occurs in the adipose tissue itself. Adipose depots in different parts of the body have different biochemical profiles. Under normal conditions, it provides feedback for hunger and diet to the brain.

The mushroom has a thin cobweb-like partial veil that does not last long before disappearing; sometimes, the partial veil leaves an annular zone on the stipe that may be darkened by spores. The flesh is thin and membrane-like, and roughly the same color as the surface tissue. It has a farinaceous (similar to freshly ground flour) odor and taste. All parts of the mushroom will stain a bluish color if handled or bruised, and it may naturally turn blue with age.

In the name of national security, Xi's government has passed numerous laws including the Counterespionage Law in 2014, the National Security Law and the Counterterrorism Law in 2015, the Cybersecurity Law and the Law on Administration of Foreign NGOs' Activities within China in 2016, the National Intelligence Law in 2017, and the Data Security Law in 2021. Under Xi, China's mass surveillance network has dramatically grown, with comprehensive profiles being built for each citizen. Grid-style social management, which involves subdividing China's counties into smaller zones, and assigning each zone to a person that reports all activity to the local government on a regular basis, has risen in prominence under Xi. Public security spending has increased significantly under Xi, reaching $210 billion in 2020, more than double from the decade prior; this was accompanied by a significant decrease in crime. Xi's leadership has also seen a more prominent role taken by the Ministry of State Security, which expanded its public profile.

== Role as a trade association == The National Independent Laboratory Association (NILA) functions as a trade association for community, regional, and health systems clinical laboratories. NILA has a long history of defending the clinical laboratory industry from legislation that would be detrimental and costly to both the clinical laboratory and patients in the United States. One of their first victories prevented the reinstatement of the 20% copayment on Part B Clinical Laboratory Fee Schedule (CLFS) payments. The organization is currently playing a role in preventing PAMA's proposed fee cuts

== See also == List of investigational drugs List of investigational generalized anxiety disorder drugs List of investigational social anxiety disorder drugs List of investigational post-traumatic stress disorder drugs List of investigational anxiety disorder drugs

Sources: en.wikipedia.org

Notes from published material

=== Tuberous sclerosis complex === Sirolimus also shows promise in treating tuberous sclerosis complex (TSC), a congenital disorder that predisposes those afflicted to benign tumor growth in the brain, heart, kidneys, skin, and other organs. After several studies conclusively linked mTOR inhibitors to remission in TSC tumors, specifically subependymal giant-cell astrocytomas in children and angiomyolipomas in adults, many US doctors began prescribing sirolimus (Wyeth's Rapamune) and everolimus (Novartis's RAD001) to TSC patients off-label. Numerous clinical trials using both rapamycin analogs, involving both children and adults with TSC, are underway in the United States.

The expectation to experience rejection can become an important stressor for transgender and gender non-conforming individuals. Mental health problems among trans people are related to higher rates of self-harm, drug usage, and suicidal ideations and attempts.

== Management == Biomedical waste must be properly managed and disposed of to protect the environment, general public and workers, especially healthcare and sanitation workers who are at risk of exposure to biomedical waste as an occupational hazard. Steps in the management of biomedical waste include generation, accumulation, handling, storage, treatment, transport and disposal. The development and implementation of a national waste management policy can improve biomedical waste management in health facilities in a country.

== Accurate mass == The accurate mass (more appropriately, the measured accurate mass) is an experimentally determined mass that allows the elemental composition to be determined. For molecules with mass below 200 Da, 5 ppm accuracy is often sufficient to uniquely determine the elemental composition.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Network